Lidokain Noridem (Lidocaine Hydrochloride Monohydrate)

Lidokain Noridem is a local anesthetic used in procedures that require temporary sensory blockade.

• Minor surgical procedures: provides targeted loss of sensation to facilitate painless incisions and suturing.
• Epidural analgesia: delivers analgesic effect during labor or postoperative pain management.
• Infiltration anesthesia: numbs tissue for dental, dermatologic or minor orthopedic interventions.

• Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the rapid influx of sodium ions required for depolarization. This inhibition stops the generation and propagation of nerve impulses, resulting in a reversible loss of sensory and, at higher concentrations, motor function in the administered area.

Lidokain Noridem may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Transient burning or stinging at the injection site
• Mild dizziness or light‑headedness
• Nausea or mild gastrointestinal upset
• Tingling or numbness extending beyond the target area

Serious or Rare Side Effects

• Systemic toxicity presenting as central nervous system depression, seizures, or respiratory arrest
• Cardiac arrhythmias, including ventricular tachycardia or heart block
• Severe allergic reactions such as urticaria, angioedema, or anaphylaxis

Prior to administration, clinicians should observe several safety measures.

• Assess patient allergy: confirm no known hypersensitivity to lidocaine or amide‑type anesthetics.
• Evaluate cardiac status: avoid or use with caution in patients with severe conduction disorders or recent myocardial infarction.
• Consider dosage limits: adhere to recommended maximum dose based on patient weight and site of administration.
• Monitor for CNS signs: watch for dizziness, tinnitus, or seizures during and after injection.
• Store at room temperature: keep in original container, protect from moisture and light.

Lidokain Noridem can interact with other medicines that affect cardiac conduction or metabolism.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): may increase plasma lidocaine concentrations and risk of toxicity.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise systemic exposure.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance lidocaine’s cardiac depressant effects.
• General anesthetics (e.g., propofol, volatile agents): additive central nervous system depression.
• Diuretics (e.g., furosemide): may alter protein binding and affect plasma levels.